• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Stroke and myocardial infarction in patients with abdominal aortic aneurysms and new-onset atrial fibrillation
Conclusion Cardiovascular prognosis has improved in patients with prevalent AAA disease and new-onset AF in concordance with optimization of antithrombotic therapy over time. A diagnosis of AF conferred residual risk of stroke and myocardial infarction.PMID:36626930 | DOI:10.1055/a-2009-8954
Source: Thrombosis and Haemostasis - January 10, 2023 Category: Hematology Authors: Chalotte Winther Winther Nicolajsen Peter Br ønnum Nielsen Martin Jensen Nikolaj Eldrup Torben Bjerregaard Larsen Gregory Yh Lip Samuel Z Goldhaber Mette S øgaard Source Type: research

Atrial fibrillation, liver cirrhosis, thrombosis, and bleeding: A  Danish population-based cohort study
CONCLUSION: In patients with AFF, liver cirrhosis was associated with an elevated risk of ischemic stroke, venous thromboembolism, and all evaluated bleeding complications.PMID:35229067 | PMC:PMC8867136 | DOI:10.1002/rth2.12668
Source: Thrombosis and Haemostasis - March 1, 2022 Category: Hematology Authors: Emil B Riahi Kasper Adelborg Lars Pedersen S øren R Kristensen Anette T Hansen Henrik T S ørensen Source Type: research

Thromboembolic events related to atrial fibrillation during the COVID-19 epidemic in Denmark
The COVID-19 epidemic has threatened to overwhelm the health-care systems of European countries resulting in government decisions of extensive societal lockdowns. There have been considerable concerns regarding the collateral effects of the COVID-19 epidemic overshadowing the care of patients with other medical conditions including cardiovascular diseases. Of interest, decreases in the registered incidences of atrial fibrillation (AF) and ischemic stroke have been reported [1,2]. AF is a common reason for physician contact and AF patients are often recommended treatment with oral anticoagulants to mitigate the associated r...
Source: Thrombosis Research - July 29, 2020 Category: Hematology Authors: Peter Vibe Rasmussen, Paul Blanche, Jarl Emanuel Strange, Jawad Haider Butt, Frederik Dalgaard, Kristian Kragholm, Matthew Phelps, Gunnar Gislason, Morten Lock Hansen Tags: Letter to the Editors-in-Chief Source Type: research

Should the Presence or Extent of Coronary Artery Disease be Quantified in the CHA2DS2-VASc Score in Atrial Fibrillation? A Report from the Western Denmark Heart Registry.
CONCLUSION:  Presence, but not extent, of CAD was an independent risk factor of the composite thromboembolic endpoint beyond the components already included in the CHA2DS2-VASc score. Consequently, we suggest that significant angiographically proven CAD should be included in the vascular disease criterion in the CHA2DS2-VASc score. PMID: 30419601 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 12, 2018 Category: Hematology Authors: Steensig K, Olesen KKW, Thim T, Nielsen JC, Jensen SE, Jensen LO, Kristensen SD, Bøtker HE, Lip GYH, Maeng M Tags: Thromb Haemost Source Type: research

Understanding the Value of Real-World Evidence: Focus on Stroke Prevention in Atrial Fibrillation with Rivaroxaban.
Abstract Real-world data are a well-recognized component within the drug lifecycle, and such data are generated from a range of sources and study designs, including claims databases, electronic health records, non-interventional studies (NIS) and registries. While this information can be of vital clinical importance, there may be challenges in understanding the relevance of the differing study designs, endpoints and populations. Here, we summarize the value of real-world evidence and considerations pertinent to their use in clinical research. Owing to the variety of analyses being conducted using real-world data, ...
Source: Thrombosis and Haemostasis - March 22, 2018 Category: Hematology Authors: Camm AJ, Coleman CI, Larsen TB, Nielsen PB, Tamayo CS Tags: Thromb Haemost Source Type: research

Predicted risk of stroke and bleeding and use of oral anticoagulants in atrial fibrillation: Danish nationwide temporal trends 2011 –2016
We used Danish nationwide registries to examine temporal trends in the predicted stroke and bleeding risks (mean CHA2DS2-VASc and HAS-BLED scores per year, respectively) as well as the combination of selected stroke and bleeding risk factors per year among atrial fibrillation (AF) patients initiated for the first time between 2011 and 2016 on vitamin K antagonists (VKAs), dabigatran, rivaroxaban, or apixaban.
Source: Thrombosis Research - October 16, 2017 Category: Hematology Authors: Alexandar Dukanovic, Laila Staerk, Emil Loldrup Fosb øl, Kasper Gadsbøll, Gunnar Hilmar Gislason, Jonas Bjerring Olesen Tags: Full Length Article Source Type: research